EcoDrugPlus

Dna Topoisomerase Ia

Ensembl ID : ENSECRG00000009339
Gene Symbol: TOP1A
1 Cross references
274 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSECRG00000013922
Gene Symbol: EML4
3 Cross references
214 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSECRG00000003043
Gene Symbol: EPHA3
3 Cross references
216 Possible Orthologues:

Eph Receptor B4

Ensembl ID : ENSECRG00000008747
Gene Symbol: EPHB4
3 Cross references
170 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSECRG00000012122
Gene Symbol: F2RL3
3 Cross references
190 Possible Orthologues:

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion

Ensembl ID : ENSECRG00000006317
Gene Symbol: FAU
3 Cross references
223 Possible Orthologues:

Fxyd Domain-Containing Ion Transport Regulator 3-Like

Ensembl ID : ENSECRG00000018732
Gene Symbol: LOC114667379
2 Cross references
285 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSECRG00000006091
Gene Symbol: FYN
3 Cross references
264 Possible Orthologues:

G Protein-Coupled Receptor 119

Ensembl ID : ENSECRG00000016539
Gene Symbol: GPR119
3 Cross references
173 Possible Orthologues:

Hck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSECRG00000011059
Gene Symbol: HCK
3 Cross references
206 Possible Orthologues:

Janus Kinase 1

Ensembl ID : ENSECRG00000009148
Gene Symbol: JAK1
3 Cross references
240 Possible Orthologues:

Janus Kinase 2

Ensembl ID : ENSECRG00000017718
Gene Symbol: JAK2
3 Cross references
265 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).